Research programme: CNS disorder therapeutics - Promentis Pharmaceuticals

Drug Profile

Research programme: CNS disorder therapeutics - Promentis Pharmaceuticals

Alternative Names: Antioxidants - Promentis Pharmaceuticals; Glutamate signalling modulators - Promentis Pharmaceuticals

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Marquette University; Promentis Pharmaceuticals; University of Wisconsin at Milwaukee
  • Developer Promentis Pharmaceuticals
  • Class Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Antioxidants; Glutamate receptor modulators; SLC7A11 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Psychiatric disorders
  • No development reported Parkinson's disease; Pervasive child development disorders; Schizophrenia

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for research development in Pervasive-child-development-disorders in USA
  • 30 Mar 2017 Preclinical trials in Psychiatric disorders in USA (unspecified route)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top